Akebia Therapeutics vs CorMedix
AKBA and CRMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AKBA and CRMD compare
CorMedix is the larger company, worth 2.8 times as much as Akebia Therapeutics ($363M against $131M).
CorMedix grew revenue faster over the last twelve months (92.5% versus −12.4% for Akebia Therapeutics).
CorMedix keeps more of each dollar of sales as profit, with a net margin of 15.5% compared with −22.6% at Akebia Therapeutics.
CorMedix scores higher on the StockData Score (15 against 4 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AKBA | CRMD |
|---|---|---|
| Size and price | ||
| Market cap | $131M | $363M |
| Share price | $0.474 | $4.66 |
| Change, 1 year | −74.4% | −59.2% |
| Change, 5 years | −82.9% | −9.2% |
| Beta (5Y) | 1.10 | 1.37 |
| Employees | 194 | 191 |
| StockData Score | ||
| Total score | 4 | 15 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 3 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× (better) | 0.9× |
| P/B | 6.5× | 0.8× (better) |
| EV/EBITDA | – | 0.1× |
| P/FCF | 9.5× | 1.2× (better) |
| FCF yield | 10.5% | 84.8% (better) |
| Fair value | – | $34.62 |
| Margin of safety | – | 86.5% |
| Growth | ||
| Revenue growth (TTM) | −12.4% | 92.5% (better) |
| Revenue growth, 5Y average | −4.3% | 320% (better) |
| Net income growth (TTM) | – | −60.7% |
| Profitability | ||
| Gross margin | 78.9% (better) | 77.5% |
| Operating margin | −15.7% | 38.6% (better) |
| Net margin | −22.6% | 15.5% (better) |
| FCF margin | 7.0% | 74.6% (better) |
| Return on equity | −144% | 15.3% (better) |
| Return on invested capital | – | 37.4% |
| Financial health | ||
| Debt / equity | 2.47 (better) | 0.00 |
| Current ratio | 1.36 | 2.43 (better) |
| Altman Z-score | −6.30 | 1.69 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | −3.1% |
| Shareholder yield | 0.00% (better) | −3.1% |
| Ownership | ||
| Held by institutions | 39.7% | 56.5% |
| Held by insiders | 2.9% | 3.2% |
| Insider net buying, 12 months | −$876K (better) | −$2.0M |
| Short interest, % of float | 10.1% | 18.8% |
Go deeper
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
- CRMD stock overview
- CRMD income statement
- CRMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.